73.44
Schlusskurs vom Vortag:
$72.00
Offen:
$71.71
24-Stunden-Volumen:
2.44M
Relative Volume:
1.45
Marktkapitalisierung:
$13.03B
Einnahmen:
$342.96M
Nettoeinkommen (Verlust:
$-864.29M
KGV:
-13.23
EPS:
-5.55
Netto-Cashflow:
$-636.03M
1W Leistung:
-4.09%
1M Leistung:
-9.94%
6M Leistung:
+0.58%
1J Leistung:
+179.24%
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
INSM
Insmed Inc
|
73.44 | 13.03B | 342.96M | -864.29M | -636.03M | -5.55 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-04-23 | Eingeleitet | Truist | Buy |
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
2023-07-26 | Eingeleitet | Guggenheim | Buy |
2022-12-09 | Eingeleitet | Mizuho | Buy |
2022-12-07 | Eingeleitet | Barclays | Overweight |
2022-11-18 | Eingeleitet | BofA Securities | Buy |
2022-04-27 | Eingeleitet | Goldman | Buy |
2021-12-06 | Eingeleitet | JP Morgan | Overweight |
2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2020-12-17 | Eingeleitet | Berenberg | Buy |
2020-10-12 | Fortgesetzt | Stifel | Buy |
2019-09-03 | Eingeleitet | Goldman | Buy |
2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2018-07-23 | Eingeleitet | Goldman | Neutral |
2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
2017-09-05 | Bestätigt | Evercore ISI | Outperform |
2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
2016-03-15 | Eingeleitet | Stifel | Buy |
2015-11-09 | Herabstufung | UBS | Buy → Neutral |
2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
2015-06-09 | Eingeleitet | Citigroup | Neutral |
2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed Incorporated (INSM): Insiders Were Dumping in Q1 2025 - Insider Monkey
Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Benzinga
Breakthrough Data: Insmed's Phase 3 Trial Could Transform Bronchiectasis Treatment - Stock Titan
Insmed’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada
Insmed’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
Insmed reports preclinical data on INS-1201 for DMD - BioWorld MedTech
Insmed CEO William Lewis sells $1.97 million in stock By Investing.com - Investing.com Australia
Insmed’s stock should triple after positive drug trial data, analyst says - MSN
H.C. Wainwright maintains Buy on Insmed stock, $90 target By Investing.com - Investing.com Canada
Insmed CEO William Lewis sells $1.97 million in stock - Investing.com India
Expert Outlook: Insmed Through The Eyes Of 13 Analysts - Benzinga
RBC maintains Outperform on Insmed stock, price target at $100 By Investing.com - Investing.com Canada
Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Truist maintains Buy on Insmed stock, sees PAH data as positive - Investing.com Australia
US Bancorp DE Boosts Holdings in Insmed Incorporated (NASDAQ:INSM) - Defense World
Truist maintains Buy on Insmed stock, sees PAH data as positive By Investing.com - Investing.com South Africa
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch By Investing.com - Investing.com South Africa
Insider Sell: Roger Adsett Sells 42,975 Shares of Insmed Inc (IN - GuruFocus.com
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch - Investing.com
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Smartleaf Asset Management LLC - Defense World
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -March 10, 2025 at 08:01 am EDT - Marketscreener.com
Insmed Expands Team with Stock Options Grant to 18 New Hires - StockTitan
UBS Group Raises Insmed (NASDAQ:INSM) Price Target to $110.00 - Defense World
Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating - TipRanks
UBS raises Insmed stock price target to $110 By Investing.com - Investing.com UK
UBS raises Insmed stock price target to $110 - Investing.com India
Insmed CEO Lewis sells $1.99 million in stock By Investing.com - Investing.com Australia
Insmed CEO Lewis sells $1.99 million in stock - Investing.com India
Amalgamated Bank Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Sanctuary Advisors LLC Acquires 464 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
RBC Capital starts Insmed at Outperform on brensocatib launch momentum - MSN
Guggenheim Reaffirms Buy Rating for Insmed (NASDAQ:INSM) - MarketBeat
Investor Network: Insmed Incorporated to Host Earnings Call - ACCESS Newswire
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - insights.citeline.com
Truist Financial Corp Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed (NASDAQ:INSM) Now Covered by Royal Bank of Canada - MarketBeat
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates - MSN
RBC Capital Initiates Coverage of Insmed (LSE:0JAV) with Outperform Recommendation - Nasdaq
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga
RBC Capital sets $100 price target on Insmed stock with Outperform rating - Investing.com Canada
RBC Capital Initiates Coverage of Insmed (INSM) with Outperform Recommendation - MSN
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says -February 25, 2025 at 12:09 pm EST - Marketscreener.com
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Lewis William | Chair and CEO |
Mar 17 '25 |
Option Exercise |
22.76 |
18,750 |
426,750 |
352,936 |
Lewis William | Chair and CEO |
Mar 17 '25 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
Lewis William | Chair and CEO |
Mar 17 '25 |
Sale |
77.03 |
18,750 |
1,444,241 |
334,186 |
Lewis William | Chair and CEO |
Mar 17 '25 |
Sale |
77.04 |
6,830 |
526,179 |
233,924 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):